AI주식인사이트AI Stock Insight
B

신신제약

002800KOSDAQ의약품 제조업

68.1 / 100

Reference Date: 2026-04-13

Financial Score32.0 / 40
News Sentiment18.1 / 25
Momentum8.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health and ROE significantly exceeds the industry average is also solid. Slightly down 3.0% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Shinshin Pharmaceutical specializes in manufacturing and selling OTC medications, particularly topical products for muscle and joint pain. The company primarily sells to pharmacies and wholesale distributors, maintaining direct sales with over 12,000 pharmacies nationwide and actively expanding exports, especially to Southeast Asia.

Number of Employees

369people

Average Salary

59.9M KRW

Score Calculation Basis

Detailed Financial Score

PER
9.00Industry Average 14.806.5Point

Lower than industry avg (good)

PBR
1.12Industry Average 1.042.5Point

Higher than industry avg (caution)

ROE
13.25Industry Average 4.427.0Point

3.0x industry avg (excellent)

Debt Ratio
3.51Industry Average 11.988.0Point

Half of industry avg (excellent)

Trend 2023~20258.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲5.3% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲35.7% (2-year basis)

ROE Trend
3.0 / 4

Avg ROE 9.5% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 3Neutral 0Negative 0Average Sentiment Score 80

Detailed Momentum

52-week position1.0Point

Near 52w low (17%, downtrend)

Current 5,520Won52-week high 7,49052-week low 5,090
1-month return2.0Point

1m -2.99% (slight drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral사업보고서 (2025.12)2026-03-18
  • Neutral감사보고서제출2026-03-18